肾脏局限型ANCA相关性血管炎伴无活动性组织学患者结局
这项多中心描述性研究纳入16例肾脏局限型ANCA相关性血管炎且活检无活动性病变的患者,发现基线eGFR较低和起病时需透析者更易进展至终末期肾病;免疫抑制未改善肾脏结局但与非复发相关。
要点
- 基线低eGFR和起病时透析是ESRD危险因素。
- 免疫抑制未影响肾脏结局但降低复发风险。
- 该无活动性组织学人群预后仍需更多研究。
核心结论
- 低初始eGFR和起病时透析依赖可能增加ESRD风险。
- 免疫抑制未影响肾脏结局但降低血管炎复发风险。
研究设计与样本
- 2005至2016年8个中心招募16例患者的描述性研究。
- 入组条件为ANCA阳性、血肌酐升高伴活动性尿沉渣、活检示无活动性病变的寡免疫复合物肾小球肾炎且无肾外血管炎。
主要发现
- 队列中63%为白人,75%为男性,中位年龄62岁。
- 入组时平均eGFR为24±20 ml/min per 1.73 m2,5例需透析。
- ESRD组基线eGFR更低(8±5 vs 35±18 ml/min per 1.73 m2;P=0.001)且起病时透析比例更高(83% vs 0%;P=0.001)。
- 复发组接受免疫抑制比例更低(25% vs 92%;相对风险0.27,风险差67%;P=0.03)。
临床怎么用
- 对该类患者应评估基线eGFR和起病时透析需求以识别ESRD高危者。
- 免疫抑制治疗决策需权衡肾脏获益与复发预防。
局限性
- 样本量小(N=16)且为描述性研究,结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Little is known about the anticipated disease course for individuals who present with renal-limited antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis but who lack inflammation on a kidney biopsy. The impact of immunosuppression on renal and overall survival is unknown. METHODS: Patients were recruited from 2005 to 2016 from 8 centers worldwide (N = 16) for this descriptive study. All had positive ANCA, elevated serum creatinine with active urine sediment, histologic evidence of pauci-immune glomerulonephritis without active lesions, and had no evidence of extrarenal vasculitis. We describe the characteristics of this cohort and the differences in the clinical, histologic, and therapeutic parameters of those who developed primary outcomes of end-stage renal disease (ESRD) and vasculitis relapse. RESULTS: The cohort was 63% Caucasian, and 75% were men, with a median age of 62 years. At entry, the mean ± SD estimated glomerular filtration rate (eGFR) was 24 ± 20 ml/min per 1.73 m2, and 5 patients required dialysis. Twelve patients received immunosuppressive therapy, 25% experienced disease relapse, and 38% developed ESRD. Patients who developed ESRD had lower baseline eGFRs (8 ± 5 ml/min per 1.73 m2 vs. 35 ± 18 ml/min per 1.73 m2; P = 0.001) and more often required dialysis at presentation (83% vs. 0%; P = 0.001). Patients who relapsed were less likely to receive immunosuppression (25% for the relapsed group vs. 92% for the nonrelapsed group; relative risk: 0.27, risk difference: 67%; P = 0.03). CONCLUSION: Among these patients, lower initial eGFR and dialysis dependence at presentation might increase the risk for ESRD. Immunosuppression did not affect renal outcomes in this sample of patients but was associated with a reduced risk for vasculitis relapse. More information is needed on factors that predict treatment response in this high-risk group.
引用
- Novick TK, Chen M, Scott J, et al. Patient Outcomes in Renal-Limited Antineutrophil Cytoplasmic Antibody Vasculitis With Inactive Histology. Kidney Int Rep. 2018. PMID: 29854975. doi:10.1016/j.ekir.2018.01.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。